PCVX
Vaxcyte, Inc.
$47.30
-0.09
(-0.19%)
Mkt Cap
6.83B
Volume
1,328,274
52W Range
29.08-65
Sector
Healthcare
Beta
1.30
EPS (TTM)
-6.89
P/E Ratio
-8.19
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (766.63M) | (463.93M) | (402.27M) | (223.49M) | (100.08M) | (89.22M) | (50.27M) | (29.48M) | (17.24M) |
| EPS | -5.63 | -3.80 | -4.14 | -3.44 | -1.93 | -2.97 | -14.10 | -8.12 | -4.84 |
| Free Cash Flow | (669.29M) | (475.05M) | (364.67M) | (176.44M) | (127.95M) | (47.78M) | (48.34M) | (32.24M) | (16,185) |
| FCF / Share | -4.92 | -3.89 | -3.75 | -2.72 | -2.46 | -1.62 | -12.74 | -8.88 | -0.00 |
| Operating CF | (655.58M) | (452.63M) | (296.79M) | (170.60M) | (121.39M) | (46.63M) | (47.15M) | (30.47M) | (14,963) |
| Total Assets | 3.05B | 3.51B | 1.41B | 1.01B | 324.34M | 392.83M | 65.70M | 70.80M | 39.63M |
| Total Debt | 228.84M | 71.11M | 29.22M | 17.94M | 16.78M | 0 | 161,000 | 458,000 | 4.50M |
| Cash & Equiv | 173.96M | 387.88M | 397.45M | 834.66M | 68.98M | 386.20M | 58.98M | 66.09M | 36.14M |
| Book Value | 2.69B | 3.31B | 1.24B | 953.61M | 284.02M | 345.84M | (106.37M) | (57.73M) | 30.94M |
| Return on Equity | -0.29 | -0.14 | -0.32 | -0.23 | -0.35 | -0.26 | N/A | N/A | -0.56 |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (320.62M) | (246.51M) | (212.83M) | (166.57M) | (140.72M) | (137.08M) | (103.12M) | (128.70M) | (95.02M) | (180.80M) | (92.66M) | (68.34M) |
| EPS | -2.30 | -1.81 | -1.56 | -1.22 | -1.04 | -1.12 | -0.83 | -1.10 | -0.85 | -1.73 | -0.91 | -0.70 |
| Free Cash Flow | (295.42M) | (219.26M) | (155.35M) | (101.65M) | (193.03M) | (141.43M) | (98.79M) | (166.77M) | (171.20M) | (185.88M) | (64.89M) | (60.60M) |
| FCF / Share | -2.12 | -1.61 | -1.14 | -0.75 | -1.42 | -1.15 | -0.80 | -1.42 | -1.53 | -1.78 | -0.64 | -0.62 |
| Operating CF | (280.62M) | (224.83M) | (143.31M) | (121.17M) | (166.27M) | (111.40M) | (60.71M) | (121.39M) | (159.12M) | (128.81M) | (57.55M) | (62.74M) |
| Total Assets | 3.35B | 3.05B | 3.17B | 3.31B | 3.38B | 3.51B | 3.56B | 2.09B | 2.09B | 1.41B | 1.50B | 1.50B |
| Total Debt | 116.30M | 228.84M | 84.44M | 85.84M | 87.21M | 71.11M | 27.96M | 25.58M | 27.42M | 29.22M | 13.81M | 15.21M |
| Cash & Equiv | 260.84M | 173.96M | 281.08M | 306.74M | 346.85M | 387.88M | 1.05B | 518.67M | 611.51M | 397.45M | 545.13M | 531.03M |
| Book Value | 3.00B | 2.69B | 2.89B | 3.07B | 3.20B | 3.31B | 3.42B | 1.99B | 1.98B | 1.24B | 1.40B | 1.43B |
| Return on Equity | -0.11 | -0.09 | -0.07 | -0.05 | -0.04 | -0.04 | -0.03 | -0.06 | -0.05 | -0.15 | -0.07 | -0.05 |
PCVX News
Vaxcyte, Inc. (PCVX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
Vaxcyte's Manufacturing-Backed Vaccine Platform Is Redefining The PCV Market
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults
Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte's 31-Valent Pneumococcal Conjugate Vaccine (PCV) Candidate
Bridgefront Capital LLC Increases Stock Holdings in Vaxcyte, Inc. $PCVX
Citigroup Inc. Sells 116,206 Shares of Vaxcyte, Inc. $PCVX
Vaxcyte, Inc. (PCVX) Q4 2025 Earnings Call Transcript
Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update